ArticleMicrobial cell factories2026
Efficient biosynthesis of the plant-derived diterpenoid 14-hydroxy-dehydroabietadiene in Saccharomyces cerevisiae.
Article in Microbial cell factories, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Engineered microorganisms unlock a new era of diterpenoid biomanufacturing: recent advances and future perspectives.Bioresources and bioprocessing · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
14-hydroxy-dehydroabietadiene is a precursor in biosynthesis pathway of triptolide in Tripterygium wilfordii and is vital for the production of triptolide and related diterpenes. The 14-hydroxy-dehydroabietadiene was produced in the engineered Saccharomyces cerevisiae WAT11 A-8 through expressing SmMS, TwTPS9, and TwCYP82D274 in combination with BTS1 and ERG20. The expression of TwCPR3 in the S. cerevisiae A-9 and A-10 for providing the electron donating has no obvious role to elevate the production of 14-hydroxy-dehydroabietadiene, but the 14-hydroxy-dehydroabietadiene is 302.73 µg L− 1 after changing S. cerevisiae INVsc1 strain A-13, which is 1.64 times higher than S. cerevisiae initial engineered strain A-8. The fusion of TwCYP82D274 and TwCPR3 in INVsc1 strain A-14, the 14-hydroxy-dehydroabietadiene is 340.26 µg L− 1, which is 1.85 times higher than strain A-8. After enhancing the acetyl-CoA metabolic flux, the 14-hydroxy-dehydroabietadiene is 508.01 µg L− 1 in INVsc1 strain A-15, which is 2.76 times higher than strain A-8. The 14-hydroxy-dehydroabietadiene is 612.76 µg L− 1 in INVsc1 strain A-16, which is 3.33 times higher than strain A-8 when overexpressing the truncated tHMG1. The YPDA medium was provided for engineered strain A-16 fermentation, the 14-hydroxy-dehydroabietadiene is 965.16 µg L− 1 in INVsc1 strain A-16, which is 5.24 times higher than strain A-8 in YPDA medium. These results provide a solid foundation for analyzing the biosynthesis pathway and the industrial-scale production of triptolide and related diterpenes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.